Catalent has launched its new OptiDose Design Solution, an approach that combines data-driven scientific tools with Catalent’s development expertise led by its scientific advisors. Integrating pharmaceutics, and dose form design target patient characteristics, OptiDose Design Solution aims to help craft the ideal dose form for all stakeholders and optimize the potential of a molecule.
 
“Taking patient needs and market realities into consideration earlier in the drug development process, along with critical CMC and DMPK parameters, is vital for creating a successful treatment for patients, innovators and health care professionals alike,” said Julien Meissonnier, Chief Scientific Officer at Catalent. “The OptiDose Design platform looks to evaluate all these considerations and provide options for final dose form decisions with an optimal combination of patient acceptance and adherence, differentiation versus any standard of care, manufacturability and cost.”
 
OptiDose Design Solution is available throughout Catalent’s global oral dose network.

Visit Catalent at CPhI North America Booth #1301